Related Experiment Video
Updated: May 10, 2025

06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
179
Increases in the Association Between the Rates of Synchronous and Metachronous Metastases over Time.
Ugur Yilmaz1, Steven P Rowe2, Lawrence B Marks3
1Department of Radiation Oncology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul 34865, Türkiye.
Journal of Clinical Medicine
|April 26, 2025
Summary
The link between synchronous and metachronous metastases in cancer is strengthening over time. This trend may be linked to advancements in medical imaging technologies, such as PET scans.
Area of Science:
- Oncology
- Epidemiology
- Medical Imaging
Background:
- Investigates the evolving association between synchronous and metachronous metastases across diverse cancer types.
- Examines temporal trends in metastasis patterns using a large-scale population database.
Purpose of the Study:
- To quantify the relationship between synchronous and metachronous metastasis rates over several decades.
- To determine if the association between these metastasis types has changed over time.
Main Methods:
- Retrospective analysis of the Surveillance, Epidemiology, and End Results (SEER)-8 dataset (1975-2020).
- Calculation of crude metastasis rates for 18 solid tumor types.
- Linear regression and Fisher's z-transformation to assess temporal changes in association.
Main Results:
- A significant association between synchronous and metachronous metastases was observed across all time points.
- The strength of this association demonstrated a consistent increase from 1975 to 2015.
- Correlation coefficients (R) increased from 0.59 in 1975 to 0.87 in 2015.
Conclusions:
- An increasing association between synchronous and metachronous distant metastases is evident over time.
- This trend coincides with the increased utilization of advanced imaging techniques like FDG-PET.
- Future research with novel PET radiotracers could prospectively evaluate the role of imaging in metastasis assessment.
Related Concept Videos
Tumor Progression
6.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.1K
Metastasis
5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
Cancer Survival Analysis
298
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
298
Kaplan-Meier Approach
55
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
55
Comparing the Survival Analysis of Two or More Groups
85
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
85

